Over 13 Million pneumonia patients require hospitalization per year
Each year, more than 13 million patients globally require hospitalization and treatment for pneumonia and related symptoms.
In up to 60% of cases, a pathogen is never identified
The laboratory work-up for pneumonia involves multiple tests. Traditional testing methods are limited to specific pathogens and return negative results in up to 60% of pneumonia cases.
Unlike conventional tests which only can detect a limited number of pathogens, Explify Respiratory applies an unbiased approach to finding any microorganism in a sample.
Applying metagenomic DNA and RNA sequencing enables Explify Respiratory to detect and identify bacterial, viral, and fungal pathogens by their unique genome sequences. The shift from conventional testing for preselected pathogens to an unbiased metagenomic-based approach can help identify microorganisms that have previously been missed.
Explify Respiratory is useful for identifying:
Explify Respiratory provides physicians with answers even if they aren’t sure of what pathogens to test for. The test is also useful for immunocompromised patients and patients who previously tested negative with conventional tests.
41 specimens from immunocompromised children with respiratory disease resulted negative using a battery of routine laboratory tests (e.g. negative for cultures, stains, EIA, and PCR)
Metagenomic test validation for clinical use that fulfills regulatory requirements poses unique challenges, because standard approaches used for conventional tests may not apply. The validation of Explify Respiratory including; laboratory protocols, data analysis algorithms, reference databases, and the establishment of rigorous quality control metrics was performed based on the framework proposed in The Archives of Pathology and Laboratory Medicine.
Explify Respiratory is currently available to order from ARUP Laboratories. Ordering Explify Respiratory requires no additional processes or steps than ordering other routine tests from ARUP.
IDbyDNA created The EXPRESS Protocol, an IRB approved study designed to create a broad repository of multiple specimen types from patients with any infectious syndromes with matched analyzed metagenomic results. Specimens may include blood, plasma, serum, sputum, nasal swab, bronchoalveolar lavage (BAL), tracheal aspirate/secretion, pleural fluid, cerebrospinal fluid (CSF), synovial fluid, intraocular fluid, urine, fecal, or other bodily fluids/tissues such as those obtained during clinically indicated procedures (e.g., bronchoscopy, thoracentesis, or biopsy of an infection site). If you are a researcher and interested in enrolling patients in EXPRESS contact us at EXPRESS@idbydna.com.